Otsuka America Pharmaceutical Inc

Add to Favorites

Pharmaceutical Products-Wholesale & Manufacturers, Physicians & Surgeons

Be the first to review!

CLOSED NOW

Today: 9:00 am - 5:00 pm

Tomorrow: 9:00 am - 5:00 pm

103 Years

in Business

(301) 990-0030Call Visit WebsiteVisit Website Map & DirectionsDirections2440 Research BlvdRockville, MD 20850 Write a ReviewWrite Review

Is this your business?

Customize this page.

Claim This Business

Hours

Regular Hours

Mon - Fri:	9:00 am - 5:00 pm

Places Near Rockville with Pharmaceutical Products-Wholesale & Manufacturers

Derwood (3 miles)
Gaithersburg (4 miles)
Montgomery Village (8 miles)
Potomac (10 miles)
Germantown (11 miles)
Olney (12 miles)
Kensington (13 miles)
Boyds (14 miles)
Brookeville (14 miles)
Great Falls (15 miles)

More Info

General Info

Incorporated in 1989, Otsuka America Pharmaceutical is a health care company that commercializes its products throughout North America. It offers products under the ABILIFY Tablets1 and PLETAL Tablets2 brands. The company works in collaboration with Bristol-Myers Squibb, which co-develops and co-promotes ABILIFY. Otsuka America Pharmaceutical has also merged with Meretek Diagnostics to form the Meretek Diagnostics Group under the Medical Device Division of OAPI. It focuses on neuroscience, cardiovascular, oncologic and gastrointestinal therapeutic treatments. The company operates Otsuka Maryland Research Institute, which was established as a wholly-owned subsidiary of OAPI to research and develop a variety of health care products. Otsuka America Pharmaceutical is a part of Otsuka Pharmaceutical Group.

Email

Extra Phones

Phone: (301) 424-9055

Phone: (301) 208-7113

Fax: (301) 212-8647

TollFree: (800) 562-3974

Payment method

insurance

AKA

Otsuka America Pharmaceutical Incorporated

Other Link

http://www.otsuka-us.com

Categories

Pharmaceutical Products-Wholesale & Manufacturers, Physicians & Surgeons

Gallery

Be the first to add a photo!

Reviews

Hi there!
Be the first to review!

Click to Rate

Details

Phone: (301) 990-0030

Address: 2440 Research Blvd, Rockville, MD 20850

Website: http://www.otsuka-us.com

People Also Viewed

View similar Pharmaceutical Products-Wholesale & Manufacturers

Suggest an Edit

Otsuka America Pharmaceutical Inc

General Practitioners

Emergency Care
Neuroleptic malignant syndrome (NMS), a serious condition that can lead to death. Call your healthcare provider or go to the nearest emergency room right away if you have some or all of the following signs and symptoms of NMS: high fever, confusion, changes in pulse, heart rate, and blood pressure, stiff muscles, and increased sweating.
Infectious Diseases
Otsuka acquired Visterra in 2018 to continue developing solutions for unmet needs in nephrology. Visterra is a clinical-stage biotechnology company that is committed to developing innovative antibody-based therapies for patients with kidney diseases and other hard-to-treat conditions. The Visterra pipeline includes programs targeting immunoglobulin A nephropathy and kidney diseases, as well as cancer, chronic pain, and infectious diseases. The extensive overlap in therapeutic focus between our two companies, along with a shared culture of creativity and commitment to patients, enables us to tackle the most difficult treatment challenges.
Pneumonia
Dysphagia: Esophageal dysmotility and aspiration have been associated with ABILIFY MAINTENA. Use caution in patients at risk for aspiration pneumonia.

Ophthalmologists

Ophthalmology

Pregnancy
Labor and Delivery
Age (40 years or older), race, color, ancestry, national origin, citizenship, marital status, medical condition, physical or mental disability, sex (including gender, gender identity, gender expression, pregnancy or childbirth and related medical conditions), sexual orientation, veteran or military status, genetic information (including familial genetic information).

Urology
Prior to joining Otsuka, Louis served in various senior and executive roles responsible for oncology and urology marketing at Bayer Pharmaceuticals, Sanofi-Aventis, and Boehringer Ingelheim Pharmaceuticals, where he and his teams achieved success in developing and implementing best-in-class strategic marketing plans.
Nephrology
Below is a full list of the products marketed and commercialized in the US by OAPI that have been either developed, acquired, or in-licensed by Otsuka. Our product specialties include neuroscience, digital innovation, nephrology, oncology, and medical devices.

Neurology
John received his M.D. and Ph.D. in neurobiology from Duke University in Durham, North Carolina. He completed his psychiatry residency training at the University of North Carolina, Chapel Hill, N.C., where he was also chief resident. In addition, John is a Diplomate, American Board of Psychiatry & Neurology, and a Distinguished Fellow of the American Psychiatric Association.
Autism
Otsuka’s commitment to providing innovative solutions for mental health disorders started more than 30 years ago. Our research in neuroscience has been focused on treatments for adults with schizophrenia and major depressive disorder (MDD), bipolar disorder, and other neurological and neuropsychiatric conditions, including Alzheimer disease, epilepsy, attention deficit hyperactive disorder, posttraumatic stress disorder, borderline personality disorder, and autism. Each central nervous system (CNS) disorder has its own set of treatment challenges and gaps in patient care, and we seek to address these challenges with each clinical and research milestone.
Multiple Sclerosis
Epilepsy

Attention Deficit Hyperactivity Disorder (ADHD)
Depression
Mental Health
As a leader in the mental health space, we are committed to providing a comprehensive suite of mental healthcare offerings to support Otsuka employees.
Psychiatry
Mary joined Otsuka in 1999 and has served in several medical and regulatory leaderships roles for products that advance therapeutic areas in which Otsuka operates. Prior to joining Otsuka, she worked at the University of Maryland School of Medicine within the Psychiatry department. She holds an undergraduate degree in pre-medicine and psychology and graduate degree in clinical neuropsychology.
Behavioral Health
Representatives from organizations including the National Council for Mental Health Wellbeing, Mental Health Association in New York State, California Council of Community Behavioral Health Agencies, National Alliance on Mental Health – Georgia, and Howard University were in attendance. In addition, Pennsylvania State Representative Mike Schlossberg and Casey Badmington, senior policy advisor to Senator Catherine
Anxiety

Psoriasis
Throughout his career, John has led, contributed to, or managed drug development programs across several psychiatric, neurological, immunoinflammatory and rare diseases, including schizophrenia, major depressive disorder, anxiety disorders, bipolar disorder, Duchenne muscular dystrophy, amyotrophic lateral sclerosis, myasthenia gravis, multiple sclerosis, epilepsy, Parkinson’s disease, Alzheimer’s disease, neuropathic pain, neuro injury, psoriasis and atopic dermatitis. John also has experience in substantial regulatory engagement, including with the Food and Drug Administration, Pharmaceutical and Medical Device Agency, European Medicines Agency and Paediatric Committee. Previously, he was Senior Vice President, Global Head of CNS at Parexel International.

View All Products

Provided by